

# Comparison of Improvements in Psoriatic Arthritis Disease Activity between Classes of Biologic Disease Modifying Anti-Rheumatic Drugs in Routine Clinical Practice: Findings from a Large Contemporaneous Real-World Cohort



Lauren Stevens, Roger Meng, Pam Kumparatana, Stefan Weiss | OM1, Inc, Boston, MA, USA

## Background

Psoriatic arthritis (PsA) affects over 2 million adults in the US and accounts for a significant proportion of healthcare spending, the primary driver of which is specialty drug treatment.<sup>1</sup> Long term control is best accomplished through early initiation of optimal therapy.

## Methods

The OM1 platform collects and links data from diverse sources and includes the clinical narratives of the Electronic Medical Record (EMR). The OM1 PremiOM-PsA dataset includes more than 54,000 patients with PsA. Disease activity measures were identified using advanced natural language processing. American College of Rheumatology endpoints were used to define disease severity.

## Main Findings

PsA disease activity improved with bDMARD therapy, particularly with TNF inhibitors. This study expands on prior observational studies with a larger cohort of patients in routine clinical practice.

## Objective

To assess improvements in disease activity among PsA patients in routine clinical practice on a TNF-i.

## Results

This analysis included 3,020 patients with PsA who were treated with the same bDMARD for 6 months, and who had disease activity measures at baseline and after 6 months. Patient characteristics are shown in Table 1. At baseline, 11.3% of patients were in remission, and 17.0%, 31.5% and 40.3% had low, moderate and high disease activity (Figure 1) and 2,436 patients (80.7%) were receiving a TNF-i.

Figure 1. Disease Activity among Patients with PsA




Table 1. Characteristics of Patients with PsA

Characteristic		All Patients (N=3020)
Age	Mean (SD)	52.9 (13.4)
Sex	Female	1863 (61.7%)
Race	White	2244 (75.2%)
	Unknown Race	605 (20.3%)
	Black-African-American	75 (2.5%)
	Asian	32 (1.1%)
	Multiracial	20 (0.7%)
	American Indian/Alaska Native	5 (0.2%)
	Native Hawaiian/Pacific Islander	3 (0.1%)

## References

1. [https://finance.yahoo.com/news/global-psoriatic-arthritis-treatment-market-105900551.html?guccounter=1&guce\\_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce\\_referrer\\_sig=AQAAEA7P5cJJQYy15FehvZYSFRDC5CXRMitUEBleE3YKz-1AVUkXbG9rVt5b9g6C12nYA560Ujip9uVxEx50JXIN/VIIUK9JQs-](https://finance.yahoo.com/news/global-psoriatic-arthritis-treatment-market-105900551.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAEA7P5cJJQYy15FehvZYSFRDC5CXRMitUEBleE3YKz-1AVUkXbG9rVt5b9g6C12nYA560Ujip9uVxEx50JXIN/VIIUK9JQs-)